Ekso Bionics (EKSO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power o ...

Company Performance - Ekso Bionics reported a quarterly loss of $1.24 per share, slightly worse than the Zacks Consensus Estimate of a loss of $1.20, and an improvement from a loss of $1.95 per share a year ago [1] - The company posted revenues of $2.06 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 55.57%, and down from $4.95 million in the same quarter last year [2] - Over the last four quarters, Ekso Bionics has not surpassed consensus EPS or revenue estimates [2] Stock Performance - Ekso Bionics shares have declined approximately 47.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Ekso Bionics is 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$1.35 on revenues of $4.29 million, and for the current fiscal year, it is -$5.10 on revenues of $18.22 million [7] - The outlook for the Medical - Instruments industry, where Ekso Bionics operates, is currently in the bottom 32% of over 250 Zacks industries, which may impact the stock's performance [8]